Table 1.
Patient characteristics
| Characteristics | LD-GP therapy (n = 35) |
Other regimens (n = 23) |
P value |
|---|---|---|---|
| Age, years | 0.431 | ||
| Median/mean | 68/69.9 | 72/67.6 | |
| Interquartile range | 65–77 | 60–75 | |
| Sex (%) | 0.159 | ||
| Male | 26 (74.3) | 13 (56.5) | |
| Female | 9 (25.7) | 10 (43.5) | |
| Performance status | 0.439 | ||
| 0 | 14 (40.0) | 13 (56.5) | |
| 1 | 16 (45.7) | 7 (30.4) | |
| 2 | 5 (14.3) | 3 (13.0) | |
| Site of primary tumor (%) | 0.837 | ||
| Upper urinary tract | 13 (37.1) | 10 (43.5) | |
| Bladder | 21 (60.0) | 12 (52.2) | |
| Both | 1 (2.9) | 1 (4.3) | |
| Prior treatment (%) | 0.110 | ||
| Chem | 8 (22.9) | 3 (13.0) | |
| Chem + Ope | 17 (48.6) | 12 (52.2) | |
| Chem + Rad | 6 (17.1) | 4 (17.4) | |
| Chem + Ope + Rad | 4 (11.4) | 4 (17.4) | |
| Second-/third-line (%) | 0.347 | ||
| Second-line therapy | 31 (88.6) | 22 (95.7) | |
| Third-line therapy | 4 (11.4) | 1 (4.3) |
LD-GP low-dose combined therapy of gemcitabine and paclitaxel, Chem chemotherapy, OP operation, Rad radiation